Health
Mirati to contribute $4 million grant to support SU2C research on KRAS mutant cancers – News-Medical.Net
Stand Up To Cancer and Mirati Therapeutics Inc. – a late-stage targeted oncology company – today announced that Mirati will contribute a $4 million grant to SU2C…
Stand Up To Cancer® (SU2C) and Mirati Therapeutics Inc. – a late-stage targeted oncology company – today announced that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program.
The research will focus on cancer types with unmet medical needs, and the application of tumor-agnostic strategies and molecular testing to address those needs. Certain cancers can sometimes have mutations in the KRAS gene,…
-
General22 hours agoGerman backpacker Carolina Wilga found alive in WA’s outback
-
General12 hours agoThailand punches above its weight in film creativity and cross-border appeal. Here’s why
-
General5 hours agoAFL Round 18 live updates: Bulldogs vs Crows, Giants vs Cats, Tigers vs Bombers, Dockers vs Hawks — blog, scores and stats
-
General23 hours agoVictims of crypto ATM scams lose $2.5 million as police warn older Tasmanians are targets